Since the beginning of 2023, and as of 16 February 2024, six MERS-CoV cases, including two fatalities, have been reported with the date of onset in 2023 by Saudi Arabia (5) and the United Arab Emirates (1).
This course focuses on antimicrobial stewardship as an approach to address healthcare-associated infections (HAI) resulting from multi-drug resistance organisms in acute care settings.
Since the most recent ECDC rapid risk assessment in 2021, the number of EU/EEA countries reporting hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23 has increased from four to ten and the number of cases reported to ECDC by the countries, increased from 12 to 143.
This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
Since April 2012, and as of 5 February 2024, a total of 2 617 cases of MERS-CoV, including 947 deaths, have been reported by health authorities worldwide.
Since April 2012, and as of 5 February 2024, a total of 2 617 cases of MERS-CoV, including 947 deaths, have been reported by health authorities worldwide.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 January 2024 and includes updates on SARS-CoV-2, measles, diphtheria, Middle East respiratory syndrome coronavirus (MERS-CoV) and poliomyelitis.